spacer
The Healthcare Sales & Marketing Network celebrates 23 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Integrated BioPharma 

 HSMN NewsFeed - 8 Jul 2021
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
Biopharmaceutical Personnel
 HSMN NewsFeed - 22 Mar 2021
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Dec 2020
Elevar Therapeutics Announces Licensing Agreement with Inceptua Group for Commercialization of Apealea(R) (Paclitaxel Micellar) in Europe
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 4 Sep 2020
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Aug 2020
Akebia Therapeutics Announces First Commercial Launch of VAFSEO(TM) (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 29 Jun 2020
Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 May 2020
Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
Biopharmaceuticals
 HSMN NewsFeed - 30 Jul 2019
Acerus And Aytu Bioscience To Co-Promote NATESTO(R) In The United States
Biopharmaceuticals Licensing
 HSMN NewsFeed - 29 Jul 2019
RenalytixAI Appoints Thomas McLain as President and Chief Commercial Officer
Diagnostics Personnel
 HSMN NewsFeed - 17 Jun 2019
Pfizer to Acquire Array BioPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 3 Jun 2019
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Apr 2019
Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Nov 2018
TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Aug 2018
Rockwell Medical Appoints New Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2018
I-Mab Successfully Raised USD 220 Million in Series C Funding
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 15 Aug 2017
Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 Jul 2017
Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo(R) (Telotristat Ethyl)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Jun 2017
NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy As A Recommended Treatment Option For Patients With Carcinoid Syndrome Diarrhea
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2017
Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 28 Apr 2017
FDA Approves Radius Health’s TYMLOS(TM) (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jan 2017
Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Dec 2016
Mission Therapeutics Appoints Colin Goddard as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Nov 2016
Lexicon Pharmaceuticals Acquires Exclusive Rights To Development Candidate For Neuropathic Pain From Its Alliance With Bristol-Myers Squibb
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 10 Aug 2016
Heron Therapeutics Announces U.S. FDA Approval of SUSTOL(R) (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 May 2016
Praveen Tyle, Ph.D. Joins Lexicon As Executive Vice President Of Research And Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Mar 2016
Merrimack Announces Inclusion of ONIVYDE(R) (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2015
Merrimack Announces U.S. FDA Approval of ONIVYDE(TM) (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Oct 2015
CMC Biologics Announces Appointment of New CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Sep 2015
Rockwell Medical Announces the U.S. Commercial Launch of Triferic(TM)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 14 May 2015
EPIRUS Biopharmaceuticals and mAbxience Sign Latin America Distribution Deal for Infliximab Biosimilar, BOW015
Biopharmaceuticals Distribution
 HSMN NewsFeed - 5 Jan 2015
Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Jul 2014
MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health
Biopharmaceuticals Wound Care Regulatory
 HSMN NewsFeed - 8 May 2014
MediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica
Biopharmaceuticals Wound Care Distribution
 HSMN NewsFeed - 16 Apr 2014
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Mar 2014
ThromboGenics Initiates Major Post-Marketing Patient Trial with JETREA(R) in the US
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 3 Dec 2013
J-Code for ThromboGenics' JETREA to Become Effective January 1, 2014
Biopharmaceuticals Ophthalmology Reimbursement
 HSMN NewsFeed - 5 Sep 2013
ThromboGenics Acquires Exclusive Rights from Bicycle Therapeutics to Develop and Commercialize Novel Drugs Inhibiting a Target for Diabetic Macular Edema
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 2 Sep 2013
UK's NICE Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics' JETREA(R) for Treatment of Vitreomacular Traction and Macular Hole
Biopharmaceuticals Ophthalmology Regulatory Reimbursement
 HSMN NewsFeed - 2 Aug 2013
Germany's IQWiG Confirms That ThromboGenics' JETREA(R) Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 18 Jun 2013
Rockwell Medical Receives $20 Million in New Financing
Biopharmaceuticals
 HSMN NewsFeed - 12 Jun 2013
ThromboGenics' JETREA(R) Receives Positive Initial NICE Recommendation for Vitreomacular Traction and Macular Hole
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 31 Jan 2013
Dyax Corp. and Novellus Biopharma AG Announce Partnership to Develop and Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in Latin America
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Jan 2013
ThromboGenics Receives Positive CHMP Opinion for JETREA(R)
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 4 Jan 2013
ThromboGenics Confirms JETREA(R) US Launch Date of Monday January 14th, 2013
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 6 Dec 2012
EYLEA(R) (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 27 Nov 2012
EYLEA(R) (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 18 Oct 2012
U.S. FDA Approves ThromboGenics' JETREA(R) (Ocriplasmin) for the Treatment of Symptomatic Vitreomacular Adhesion (VMA)
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 20 Aug 2012
Dyax Corp. Creates COO Position and Expands Executive Roles
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2012
XenoPort Appoints Ernest Mario, Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 5 Apr 2012
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
Biopharmaceuticals
 HSMN NewsFeed - 9 Mar 2012
Delcath Selects Quintiles to Support EU Launch of CHEMOSAT
Devices Drug Delivery Oncology
 HSMN NewsFeed - 8 Mar 2012
Regeneron and Bayer Announce Approval of EYLEA(R) (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration in Australia
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 17 Jan 2012
Alan Raffensperger appointed Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jan 2012
Gentium Appoints Swedish Orphan Biovitrum AB as Exclusive Distributor of Defibrotide in Nordic and Baltic Territories
Biopharmaceuticals Distribution
 HSMN NewsFeed - 3 Jan 2012
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA(TM) (aflibercept) Injection
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 6 Sep 2011
Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2011
ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Apr 2011
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Apr 2011
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jan 2011
Dyax and Sigma-Tau Group Expand Agreement to Commercialize KALBITOR(R) (ecallantide) for Hereditary Angioedema
Biopharmaceuticals Licensing
 HSMN NewsFeed - 20 Dec 2010
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 14 Dec 2010
Human Genome Sciences Appoints Colin Goddard, Ph.D., to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Nov 2010
Christine A. Poon Elected to Regeneron Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Aug 2010
Data from First Phase 3 Trial (EDEMA3(R)) for KALBITOR(R) (ecallantide) Published in The New England Journal of Medicine
Biopharmaceuticals
 HSMN NewsFeed - 1 Jul 2010
BioVex Appoints Steven Kelly as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Feb 2010
Immunomedics Appoints Kenneth J. Zuerblis to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jan 2010
Constellation Pharmaceuticals Appoints Industry Veteran Garen Bohlin to Senior Management Group
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2009
Quintiles and Allergan Announce Co-Promotion for Sanctura XR(R)
Biopharmaceuticals Urology
 HSMN NewsFeed - 16 Sep 2009
AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Sep 2009
FDA Grants Protalix Orphan Drug Designation for prGCD
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Aug 2009
Protalix Receives FDA Fast Track Designation for prGCD
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Jul 2009
Regeneron Receives European Medicines Agency Positive Opinion for Marketing Authorization of Rilonacept for the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 May 2009
Celldex Therapeutics, Inc. Enhances Precision Targeted Immunotherapy Platform with the Acquisition of CuraGen Corporation
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Apr 2009
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Apr 2009
XenoPort Announces Election of Co-Promotion Option for Solzira
Biopharmaceuticals
 HSMN NewsFeed - 2 Mar 2009
Rockwell Medical Technologies, Inc. Appoints Richard Yocum, M.D. as VP of Drug Development and Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Nov 2008
Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Nov 2008
Integrated BioPharma, Inc. Announces New Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Oct 2008
Study Published in New England Journal of Medicine Shows K-ras Gene Mutation Status May Affect Response to ERBITUX(R) Treatment
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Oct 2008
Omrix Biopharmaceuticals Receives Approval from European Medicines Agency for Evicel Liquid Fibrin Sealant (Human)
Biopharmaceuticals Wound Care Regulatory
 HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Sep 2008
AVANT Immunotherapeutics Announces Name Change to Celldex Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Aug 2008
Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular Degeneration
Biopharmaceuticals Opthalmology
 HSMN NewsFeed - 25 Jul 2008
Omrix Biopharmaceuticals Receives Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for Evicel(TM) Liquid Fibrin Sealant (Human)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Jun 2008
ImClone Appoints Dr. Bernhard Ehmer Senior Vice President and Managing Director, International Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2008
New Analyses of Pivotal Phase 3 Study of ERBITUX(R) Demonstrate Enhanced Efficacy in First-Line Metastatic Colorectal Cancer Patients with Wild-Type K-Ras Biomarker
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2008
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 May 2008
Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 28 Apr 2008
Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 22 Apr 2008
ImClone Announces Agreement with FDA on Special Protocol Assessment for Phase III Study of IMC-1121B in Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2008
Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID(R) to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2008
ImClone Appoints Kenneth J. Zuerblis Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Mar 2008
ARCALYST(TM) (rilonacept), First and Only FDA-approved Treatment for Cryopyrin-Associated Periodic Syndromes (CAPS), Now Available in the United States
Biopharmaceuticals
 HSMN NewsFeed - 24 Mar 2008
Accentia Biopharmaceuticals Announces Results on Primary Endpoint in Clinical Study of SinuNase Lavage
Biopharmaceuticals
 HSMN NewsFeed - 18 Mar 2008
FDA issues Approvable Letter for ceftobiprole, a new anti-MRSA broad-spectrum antibiotic
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Feb 2008
Arbor Pharmaceuticals, Inc. Announces Agreement with Accentia Biopharmaceuticals, Inc. to Launch Company’s Second Pediatric Treatment
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2008
Omrix Biopharmaceuticals Announces Key Changes to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Dec 2007
Protalix BioTherapeutics Announces Resignation of Board Members
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Nov 2007
Published Data Suggest That ERBITUX(R) Enables Complete Surgical Resection of Colorectal Liver Metastases in Patients Previously Refractory to Conventional Systemic Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2007
New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2007
AVEO Pharmaceuticals Appoints David Johnston as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Oct 2007
ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2007
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Oct 2007
Basilea Announces Positive Top-line Data from Phase III Study of Ceftobiprole in Hospital-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
Accentia Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Oct 2007
Accentia Biopharmaceuticals Announces Completion of Enrollment in Fast-Tracked Pivotal Phase 3 Clinical Trial of SinuNase for Chronic Sinusitis
Biopharmaceuticals
 HSMN NewsFeed - 2 Oct 2007
Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Sep 2007
ImClone Systems Expands IMC-A12 Development with Ten New Planned Clinical Trials
Biopharmaceuticals
 HSMN NewsFeed - 14 Sep 2007
Canadian Regulatory Authority has Accepted for Review New Drug Submission for Ceftobiprole
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2007
ImClone Settles Patent Lawsuit and Gains Rights to Additional Intellectual Property
Biopharmaceuticals Oncology Litigation Licensing
 HSMN NewsFeed - 28 Aug 2007
OMRIX Biopharmaceuticals Receives Food and Drug Administration (FDA) Approval for Thrombin Stand Alone, EVITHROM* Thrombin, Topical (Human), with General Hemostasis in Surgery Indication
Biopharmaceuticals Wound Care Surgery FDA
 HSMN NewsFeed - 27 Aug 2007
Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Biopharmaceuticals
 HSMN NewsFeed - 15 Aug 2007
Accentia Biopharmaceuticals Updates Interim Analysis of Blinded Clinical Results in the Fast-Tracked Pivotal Phase 3 Trial of SinuNase for the Treatment of Refractory Chronic Sinusitis
Biopharmaceuticals
 HSMN NewsFeed - 9 Aug 2007
ImClone Systems Appoints John H. Johnson Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Aug 2007
Newly Created Hemosol BioPharma Inc. on the Hunt for Partnership, Licensing and Acquisition Targets
Biopharmaceuticals Licensing
 HSMN NewsFeed - 31 Jul 2007
Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 30 Jul 2007
OMRIX Biopharmaceuticals Submits Market Authorization Application (MAA) to European Medicines Agency (EMEA) for Approval to Market Evicel(TM) with General Hemostasis Indication
Biopharmaceuticals Surgery Regulatory
 HSMN NewsFeed - 27 Jul 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jul 2007
ImClone Systems Appoints Thomas F. Deuel to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jul 2007
OMRIX Biopharmaceuticals Receives Food and Drug Administration (FDA) Approval to Use Cryoprecipitate from Talecris Biotherapeutics, Inc. in Its Manufacturing Process
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jun 2007
FDA Accepts and Grants Priority Review of ERBITUX(R) (Cetuximab) sBLA for Overall Survival in Patients with Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
Biovest to File for Accelerated Conditional Approval of BiovaxID
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 May 2007
OMRIX Biopharmaceuticals Receives Food and Drug Administration (FDA) Approval for Liquid Fibrin Sealant, Evicel(TM), For Use in Vascular Surgery
Devices FDA
 HSMN NewsFeed - 14 May 2007
Accentia Biopharmaceuticals Makes Milestone Payment Based on Fast Tracked Pivotal Phase 3 Study with SinuNase for the Treatment of Chronic Sinusitis
Biopharmaceuticals
 HSMN NewsFeed - 10 May 2007
ImClone Systems Appoints Jules Haimovitz to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 May 2007
OMRIX Biopharmaceuticals Submits Regulatory Filing for Hepatitis B Immunoglobulin (HBIG) in Sweden
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 May 2007
Integrated BioPharma to Explore Divesting Its Biotechnology Business
Biopharmaceuticals
 HSMN NewsFeed - 26 Apr 2007
Lexicon Genetics Changes Name to Lexicon Pharmaceuticals as Drug Development Pipeline Progresses
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2007
Randomized Phase III Trial Showed ERBITUX Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2007
Data Available from ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2007
OMRIX Biopharmaceuticals Announces Departure of Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Apr 2007
Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Mar 2007
AEterna Zentaris Announces Appointment of New President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Mar 2007
OMRIX Biopharmaceuticals Submits Supplemental Biologics License Application (sBLA) to Market Evicel With General Hemostasis in Surgery Indication
Biopharmaceuticals Surgery
 HSMN NewsFeed - 6 Feb 2007
ImClone Systems Opts-out of Development Agreement with UCB to Focus Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121B
Biopharmaceuticals
 HSMN NewsFeed - 5 Feb 2007
ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Jan 2007
ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Dec 2006
Advaxis Names Thomas A. Moore to Serve as CEO and Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2006
Dr. Bob Tepper, President of R&D, to Leave Millennium
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Nov 2006
Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2006
Carl C. Icahn Appointed Chairman of ImClone Systems
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Oct 2006
ImClone Systems Appoints Peter S. Liebert, M.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Oct 2006
ImClone Systems Directors Urge Stockholders to Reject Carl Icahn's Efforts to Opportunistically Seize Control of the Company
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2006
ImClone Systems Promotes Ana I. Stancic to Senior Vice President, Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Sep 2006
Avalon Pharmaceuticals Appoints David D. Muth to Executive Vice President, Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Sep 2006
ImClone Systems Issues Statement on Court Ruling in Litigation against Yeda
Biopharmaceuticals Oncology Licensing Litigation
 HSMN NewsFeed - 13 Sep 2006
FibroGen Appoints Melissa L. Grigorieff, Vice President of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Aug 2006
Prestwick Pharmaceuticals Appoints George F. Horner III as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Aug 2006
Momenta Pharmaceuticals Announces Appointment of Craig A. Wheeler as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Aug 2006
ImClone Systems Completes Review of Strategic Alternatives and Decides to Remain Independent
Biopharmaceuticals
 HSMN NewsFeed - 2 Aug 2006
ImClone Systems Promotes Michael P. Bailey to Senior Vice President, Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jul 2006
ImClone Systems Issues Statement Regarding Repligen Litigation
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 20 Jul 2006
ImClone Systems and Merck KGaA Amend and Supplement ERBITUX Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Jul 2006
Nuvelo Appoints H. Ward Wolff as Chief Financial Officer and Jill M. Pergande as Vice President, Human Resources
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2006
ImClone Systems Names Elizabeth Yamashita Vice President, Regulatory CMC and Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 May 2006
ESBATech AG Announces Appointment of James Egan as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 May 2006
AVANIR Pharmaceuticals Hires Michael J. Puntoriero to Serve as Senior Vice President of Finance and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Apr 2006
Abraxis BioScience Announces Co-Promotion Agreement with AstraZeneca for ABRAXANE(R) in the U.S. and the Acquisition of AstraZeneca's U.S. Branded Anesthetic and Analgesic Product Lines
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 25 Apr 2006
Abraxis BioScience to Acquire European and U.S. Compliant Manufacturing Complex from Pfizer
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2006
FibroGen Appoints Tim C. Opler, Vice President of Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2006
ImClone Systems Issues Statement Regarding European Commission Approval for ERBITUX(R) for the Treatment of Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Apr 2006
ImClone Systems Announces Receipt of $250 Million Milestone Payment from Bristol-Myers Squibb
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2006
Morphotek Announces Appointments and Promotions to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Mar 2006
MannKind Initiates Two U.S. Pivotal Phase 3 Studies of Inhaled Technosphere(R) Insulin
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 1 Mar 2006
FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Feb 2006
ImClone Systems Issues Statement Regarding Positive Opinion from CHMP for Use of ERBITUX(R) in Head and Neck Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Feb 2006
ImClone Systems Announces Complete Enrollment of Several Studies Examining Potential Survival Benefit Of ERBITUX(R) In Three Major Cancer Types
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Feb 2006
ImClone Systems Promotes Richard Crowley to Senior Vice President, Biopharmaceutical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Feb 2006
CuraGen and TopoTarget Initiate Phase II Clinical Trial of PXD101 for T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2006
ImClone Systems Engages Lazard to Review Strategic Alternatives for the Company
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2006
ImClone Systems Names Cheryl Anderson Vice President, Regulatory Affairs
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 133

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 133 additional stories matching:
Integrated BioPharma
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.